iScience | |
A high-throughput liquid bead array assay confirms strong correlation between SARS-CoV-2 antibody level and COVID-19 severity | |
Eric Brady1  Gordon R. Bernard2  Jillian P. Rhoads2  Sandra Yoder2  Isaac Thomsen3  C. Buddy Creech4  Allison P. Wheeler4  Monique Bennett5  Jill M. Pulley5  Thomas G. Stewart5  | |
[1] Vanderbilt Institute for Infection, Immunology and Inflammation (VI4), Vanderbilt University Medical Center, Nashville, TN, USA;Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, TN, USA;Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA;Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA;Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; | |
关键词: Biological Sciences; Microbiology; Virology; Viral Microbiology; | |
DOI : | |
来源: DOAJ |
【 摘 要 】
Summary: A detailed understanding of the adaptive host response to SARS-CoV-2 infection in humans is urgently needed. We developed a sensitive, high-throughput, and efficient assay using liquid bead array technology. We observed advantages over traditional ELISA for the detection and quantification of binding IgG against the receptor binding domain (RBD) of SARS-CoV-2. To determine whether COVID-19 symptom severity correlates with SARS-CoV-2 IgG, we measured anti-RBD IgG levels from 67 subjects recovered from PCR-confirmed COVID-19. We found that COVID-19 symptom severity strongly correlated with RBD IgG level (p < 0.001). These findings have substantial implications for public policy surrounding assessments of antibody responses and possible immunity, as not all cases of COVID-19 can be assumed to generate a protective antibody response, and mild disease in particular is capable of generating very low-level anti-RBD IgG levels. These findings also have important implications for the selection of donors for convalescent plasma to be used therapeutically.
【 授权许可】
Unknown